IBDEI15U ; ; 17-FEB-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,19735,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19735,1,3,0)
 ;;=3^DM Type 1 w/ Diabetic Autonomic Polyneuropathy
 ;;^UTILITY(U,$J,358.3,19735,1,4,0)
 ;;=4^E10.43
 ;;^UTILITY(U,$J,358.3,19735,2)
 ;;=^5002607
 ;;^UTILITY(U,$J,358.3,19736,0)
 ;;=E10.59^^84^921^4
 ;;^UTILITY(U,$J,358.3,19736,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19736,1,3,0)
 ;;=3^DM Type 1 w/ Circulatory Complications
 ;;^UTILITY(U,$J,358.3,19736,1,4,0)
 ;;=4^E10.59
 ;;^UTILITY(U,$J,358.3,19736,2)
 ;;=^5002612
 ;;^UTILITY(U,$J,358.3,19737,0)
 ;;=E10.618^^84^921^5
 ;;^UTILITY(U,$J,358.3,19737,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19737,1,3,0)
 ;;=3^DM Type 1 w/ Diabetic Arthropathy
 ;;^UTILITY(U,$J,358.3,19737,1,4,0)
 ;;=4^E10.618
 ;;^UTILITY(U,$J,358.3,19737,2)
 ;;=^5002614
 ;;^UTILITY(U,$J,358.3,19738,0)
 ;;=E10.621^^84^921^7
 ;;^UTILITY(U,$J,358.3,19738,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19738,1,3,0)
 ;;=3^DM Type 1 w/ Diabetic Foot Ulcer
 ;;^UTILITY(U,$J,358.3,19738,1,4,0)
 ;;=4^E10.621
 ;;^UTILITY(U,$J,358.3,19738,2)
 ;;=^5002616
 ;;^UTILITY(U,$J,358.3,19739,0)
 ;;=E10.622^^84^921^11
 ;;^UTILITY(U,$J,358.3,19739,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19739,1,3,0)
 ;;=3^DM Type 1 w/ Skin Ulcer
 ;;^UTILITY(U,$J,358.3,19739,1,4,0)
 ;;=4^E10.622
 ;;^UTILITY(U,$J,358.3,19739,2)
 ;;=^5002617
 ;;^UTILITY(U,$J,358.3,19740,0)
 ;;=E10.65^^84^921^10
 ;;^UTILITY(U,$J,358.3,19740,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19740,1,3,0)
 ;;=3^DM Type 1 w/ Hyperglycermia
 ;;^UTILITY(U,$J,358.3,19740,1,4,0)
 ;;=4^E10.65
 ;;^UTILITY(U,$J,358.3,19740,2)
 ;;=^5002623
 ;;^UTILITY(U,$J,358.3,19741,0)
 ;;=E10.39^^84^921^9
 ;;^UTILITY(U,$J,358.3,19741,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19741,1,3,0)
 ;;=3^DM Type 1 w/ Diabetic Ophthalmic Complications NEC
 ;;^UTILITY(U,$J,358.3,19741,1,4,0)
 ;;=4^E10.39
 ;;^UTILITY(U,$J,358.3,19741,2)
 ;;=^5002603
 ;;^UTILITY(U,$J,358.3,19742,0)
 ;;=E66.3^^84^921^45
 ;;^UTILITY(U,$J,358.3,19742,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19742,1,3,0)
 ;;=3^Overweight
 ;;^UTILITY(U,$J,358.3,19742,1,4,0)
 ;;=4^E66.3
 ;;^UTILITY(U,$J,358.3,19742,2)
 ;;=^5002830
 ;;^UTILITY(U,$J,358.3,19743,0)
 ;;=E89.1^^84^921^49
 ;;^UTILITY(U,$J,358.3,19743,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19743,1,3,0)
 ;;=3^Postprocedural Hypoinsulinemia
 ;;^UTILITY(U,$J,358.3,19743,1,4,0)
 ;;=4^E89.1
 ;;^UTILITY(U,$J,358.3,19743,2)
 ;;=^5003036
 ;;^UTILITY(U,$J,358.3,19744,0)
 ;;=H40.9^^84^922^9
 ;;^UTILITY(U,$J,358.3,19744,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19744,1,3,0)
 ;;=3^Glaucoma,Unspec
 ;;^UTILITY(U,$J,358.3,19744,1,4,0)
 ;;=4^H40.9
 ;;^UTILITY(U,$J,358.3,19744,2)
 ;;=^5005931
 ;;^UTILITY(U,$J,358.3,19745,0)
 ;;=H26.9^^84^922^5
 ;;^UTILITY(U,$J,358.3,19745,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19745,1,3,0)
 ;;=3^Cataract,Unspec
 ;;^UTILITY(U,$J,358.3,19745,1,4,0)
 ;;=4^H26.9
 ;;^UTILITY(U,$J,358.3,19745,2)
 ;;=^5005363
 ;;^UTILITY(U,$J,358.3,19746,0)
 ;;=H10.9^^84^922^8
 ;;^UTILITY(U,$J,358.3,19746,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19746,1,3,0)
 ;;=3^Conjunctivitis,Unspec
 ;;^UTILITY(U,$J,358.3,19746,1,4,0)
 ;;=4^H10.9
 ;;^UTILITY(U,$J,358.3,19746,2)
 ;;=^5004716
 ;;^UTILITY(U,$J,358.3,19747,0)
 ;;=H11.32^^84^922^6
 ;;^UTILITY(U,$J,358.3,19747,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19747,1,3,0)
 ;;=3^Conjunctival Hemorrhage,Left Eye
 ;;^UTILITY(U,$J,358.3,19747,1,4,0)
 ;;=4^H11.32
 ;;^UTILITY(U,$J,358.3,19747,2)
 ;;=^5004783
 ;;^UTILITY(U,$J,358.3,19748,0)
 ;;=H11.31^^84^922^7
 ;;^UTILITY(U,$J,358.3,19748,1,0)
 ;;=^358.31IA^4^2
